AbbVie Inc.
ANTIBODIES AGAINST THE RGM A PROTEIN AND USES THEREOF

Last updated:

Abstract:

The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.

Status:
Application
Type:

Utility

Filling date:

9 Sep 2020

Issue date:

29 Jul 2021